Diagnosis and treatment of lichen sclerosus: An update

American Journal of Clinical Dermatology

Volumn 14, Issue 1, 2013, Pages 27-47

  Fistarol, Susanna K ^a   Itin, Peter H ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; ANDROGEN RECEPTOR; ANDROSTANOLONE; BETAMETHASONE DIPROPIONATE; CLOBETASOL PROPIONATE; ETRETIN; ETRETINATE; MOMETASONE FUROATE; PIMECROLIMUS; PLACEBO; PSORALEN; RETINOIC ACID; STEROID 5ALPHA REDUCTASE; TACROLIMUS; TESTOSTERONE; TRIAMCINOLONE;

ALOPECIA AREATA; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; AUTOIMMUNE THYROIDITIS; AUTOIMMUNITY; BULLOUS PEMPHIGOID; BURNING SENSATION; CHILD SEXUAL ABUSE; CIRCUMCISION; CLINICAL FEATURE; CONSTIPATION; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPAREUNIA; DYSURIA; EPSTEIN BARR VIRUS INFECTION; ERECTILE DYSFUNCTION; ERYTHEMA; EVENING DOSAGE; EXOCYTOSIS; FAMILY HISTORY; GENETIC SUSCEPTIBILITY; GENITAL EDEMA; GENITAL PRURITUS; HISTOPATHOLOGY; HUMAN; HYPERKERATOSIS; LENTIGO; LICHEN SCLEROSUS ET ATROPHICUS; LONG TERM CARE; LOSS OF FUNCTION MUTATION; LYME DISEASE; MAINTENANCE THERAPY; MELANOCYTIC NEVUS; MELANOMA; META ANALYSIS; MICTURITION DISORDER; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OPEN STUDY; PAINFUL DEFECATION; PERNICIOUS ANEMIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHIMOSIS; PHOTOCHEMOTHERAPY; PHOTODYNAMIC THERAPY; PHOTOTHERAPY; POSTMENOPAUSE; PREPUBERTY; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; PUVA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SEX DIFFERENCE; SEXUAL DYSFUNCTION; SKIN ALLERGY; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; TELANGIECTASIA; TERATOGENICITY; THYROIDITIS; TREATMENT RESPONSE; ULTRAVIOLET B RADIATION; URETHROPLASTY; VITILIGO;

ADULT; BALANITIS XEROTICA OBLITERANS; BORRELIA BURGDORFERI; CALCINEURIN; CHILD; FEMALE; GLUCOCORTICOIDS; HUMANS; LICHEN SCLEROSUS ET ATROPHICUS; MALE; PHOTOTHERAPY; RETINOIDS; VULVAR LICHEN SCLEROSUS;

EID: 84873869035     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.1007/s40257-012-0006-4     Document Type: Review

References (155)

1. Wallace HJ. Lichen sclerosus et atrophicus. Trans St Johns Hosp Dermatol Soc. 1971;57:9-30.
2. Brown AR, Dunlap CL, Bussard DA, et al. Lichen sclerosus et atrophicus of the oral cavity: report of two cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997;84:165-70.
3. Jensen T, Worsaae N, Melgaard B. Oral lichen sclerosus et atrophicus: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;94:702-6.
4. Azevedo RS, Romañach MJ, de Almeida OP, et al. Lichen sclerosus of the oral mucosa: clinicopathological features of six cases. Int J Oral Maxillofac Surg. 2009;38:855-60.
5. Neill SM, Lewis FM, Tatnall FM, et al. British Association of Dermatologists' guidelines for the management of lichen sclerosus 2010. Br J Dermatol. 2010;163:672-82.
6. Goldstein AT, Marinoff SC, Christopher K, et al. Prevalence of vulvar lichen sclerosus in a general gynecology practice. J Reprod Med. 2005;50:477-80.
7. Powell J, Wojnarowska F. Childhood vulvar lichen sclerosus: an increasingly common problem. J Am Acad Dermatol. 2001;44:803-6.
8. Kizer WS, Prarie T, Morey AF. Balanitis xerotica obliterans: epidemiologic distribution in an equal access health care system. South Med J. 2003;96:9-11.
9. Nelson DM, Peterson AC. Lichen sclerosus: epidemiological distribution in an equal access health care system. J Urol. 2011;185:522-5.
10. Meyrick Thomas RH, Ridley CM, McGibbon DH, et al. Lichen sclerosus et atrophicus and autoimmunity: a study of 350 women. Br J Dermatol. 1988;118:41-6.
11. Murphy R. Lichen sclerosus. Dermatol Clin. 2010;28:707-15.
12. Cooper SM, Ali I, Baldo M, et al. The association of lichen sclerosus and erosive lichen planus of the vulva with autoimmune disease: a case-control study. Arch Dermatol. 2008;144:1432-5.
13. Birenbaum DL, Young RC. High prevalence of thyroid disease in patients with lichen sclerosus. J Reprod Med. 2007;52:28-30.
14. Leese GP, Flynn RV, Jung RT, et al. Increasing prevalence and incidence of thyroid disease in Tayside, Scotland: the Thyroid Epidemiology Audit and Research Study (TEARS). Clin Endocrinol (Oxf). 2008;68:311-6.
15. Powell J, Wojnarowska F, Winsey S, et al. Lichen sclerosus premenarche: autoimmunity and immunogenetics. Br J Dermatol. 2000;142:481-4.
16. Lipscombe TK, Wayte J, Wojnarowska F, et al. A study of clinical and aetiological factors and possible associations of lichen sclerosus in males. Australas J Dermatol. 1997;38:132-6.
17. Azurdia RM, Luzzi GA, Byren I, et al. Lichen sclerosus in adult men: a study of HLA associations and susceptibility to autoimmune disease. Br J Dermatol. 1999;140:79-83.
18. Bjekić M, Šipetić S, Marinković J. Risk factors for genital lichen sclerosus in men. Br J Dermatol. 2011;164:325-9.
19. Oyama N, Chan I, Neill SM, et al. Autoantibodies to extracellular matrix protein 1 in lichen sclerosus. Lancet. 2003;362:118-23.
20. Edmonds EV, Oyama N, Chan I, et al. Extracellular matrix protein 1 autoantibodies in male genital lichen sclerosus. Br J Dermatol. 2011;165:218-9.
21. Chan I. The role of extracellular matrix protein 1 in human skin. Clin Exp Dermatol. 2004;29:52-6.
22. Howard A, Dean D, Cooper S, et al. Circulating basement membrane zone antibodies are found in lichen sclerosus of the vulva. Australas J Dermatol. 2004;45:12-5.
23. Baldo M, Bailey A, Bhogal B, et al. T cells reactive with the NC16A domain of BP180 are present in vulval lichen sclerosus and lichen planus. J Eur Acad Dermatol Venereol. 2010;24:186-90.
24. Baldo M, Bhogal B, Groves RW, et al. Childhood vulval lichen sclerosus: autoimmunity to the basement membrane zone protein BP180 and its relationship to autoimmunity. Clin Exp Dermatol. 2010;35:543-5.
25. Gambichler T, Höxtermann S, Skrygan M, et al. Occurrence of circulating anti-bullous pemphigoid antibodies in patients with lichen sclerosus. J Eur Acad Dermatol Venereol. 2011;25:369-70.
26. Sherman V, McPherson T, Baldo M, et al. The high rate of familial lichen sclerosus suggests a genetic contribution: an observational cohort study. J Eur Acad Dermatol Venereol. 2010;24:1031-4.
27. Marren P, Yell J, Charnock FM, et al. The association between lichen sclerosus and antigens of the HLA system. Br J Dermatol. 1995;132:197-203.
28. Sentürk N, Aydin F, Birinci A, et al. Coexistence of HLA-B*08 and HLA-B*18 in four siblings with lichen sclerosus. Dermatology. 2004;208:64-6.
29. Aslanian FM, Marques MT, Matos HJ, et al. HLA markers in familial lichen sclerosus. J Dtsch Dermatol Ges. 2006;4:842-7.
30. Gao XH, Barnardo MC, Winsey S, et al. The association between HLA DR, DQ antigens, and vulval lichen sclerosus in the UK: HLA DRB112 and its associated DRB112/DQB10301/04/09/010 haplotype confers susceptibility to vulval lichen sclerosus, and HLA DRB10301/04 and its associated DRB10301/04/DQB10201/02/03 haplotype protects from vulval lichen sclerosus. J Invest Dermatol. 2005;125:895-9.
31. Bunker CB. Male genital lichen sclerosus and tacrolimus. Br J Dermatol. 2007;157:1079-80.
32. Bunker CB, Edmonds E, Hawkins D, et al. Re: Lichen sclerosus: review of the literature and current recommendations for management: J. M. Pugliese, A. F. Morey and A. C. Peterson J Urol 2007; 178: 2268-76. J Urol. 2009;181:1502-3.
33. Edmonds EV, Hunt S, Hawkins D, et al. Clinical parameters in male genital lichen sclerosus: a case series of 329 patients. J Eur Acad Dermatol Venereol. Epub 2011 Jun 27.
34. Edmonds EC, Bunker CB. Nuclear magnetic resonance spectroscopy of urine in male genital lichen sclerosus. Br J Dermatol. 2010;163:1355-6.
35. Edmonds E, Mavin S, Francis N, et al. Borrelia burgdorferi is not associated with genital lichen sclerosus in men. Br J Dermatol. 2009;160:459-60.
36. Aberer E, Stanek G. Histological evidence for spirochetal origin of morphea and lichen sclerosus et atrophicans. Am J Dermatopathol. 1987;9:374-9.
37. Aberer E, Kollegger H, Kristoferitsch W, et al. Neuroborreliosis in morphea and lichen sclerosus et atrophicus. J Am Acad Dermatol. 1988;19:820-5.
38. Schempp C, Bocklage H, Lange R, et al. Further evidence for Borrelia burgdorferi infection in morphea and lichen sclerosus et atrophicus confirmed by DNA amplification. J Invest Dermatol. 1993;100:717-20.
39. Ranki A, Aavik E, Peterson P, et al. Successful amplification of DNA specific for Finnish Borrelia burgdorferi isolates in erythema chronicum migrans but not in circumscribed scleroderma lesions. J Invest Dermatol. 1994;102:339-45.
40. Fujiwara H, Fujiwara K, Hashimoto K, et al. Detection of Borrelia burgdorferi DNA (B garinii or B afzelii) in morphea and lichen sclerosus et atrophicus tissues of German and Japanese but not of US patients. Arch Dermatol. 1997;133:41-4.
41. Alonso-Llamazares J, Persing DH, Anda P, et al. No evidence for Borrelia burgdorferi infection in lesions of morphea and lichen sclerosus et atrophicus in Spain: a prospective study and literature review. Acta Derm Venereol. 1997;77:299-304.
42. Aberer E, Schmidt BL, Breier F, et al. Amplification of DNA of Borrelia burgdorferi in urine samples of patients with granuloma annulare and lichen sclerosus et atrophicus. Arch Dermatol. 1999;135:210-2.
43. Özkan S, Atabey N, Fetil E, et al. Evidence for Borrelia burgdorferi in morphea and lichen sclerosus. Int J Dermatol. 2000;39:278-83.
44. Breier F, Khanakah G, Stanek G, et al. Isolation and polymerase chain reaction typing of Borrelia afzelii from a skin lesion in a seronegative patient with generalized ulcerating bullous lichen sclerosus et atrophicus. Br J Dermatol. 2001;144:387-92.
45. Eisendle K, Grabner T, Kutzner H, et al. Possible role of Borrelia burgdorferi sensu lato infection in lichen sclerosus. Arch Dermatol. 2008;144:591-8.
46. Zollinger T, Mertz KD, Schmid M, et al. Borrelia in granuloma annulare, morphea and lichen sclerosus: a PCR-based study and review of the literature. J Cutan Pathol. 2010;37:571-7.
47. Aidé S, Lattario FR, Almeida G, et al. Epstein-Barr virus and human papillomavirus infection in vulvar lichen sclerosus. J Low Genit Tract Dis. 2010;14:319-22.
48. Friedrich EG Jr, Kalra PS. Serum levels of sex hormones in vulvar lichen sclerosus, and the effect of topical testosterone. N Engl J Med. 1984;310:488-91.
49. Clifton MM, Garner IB, Kohler S, et al. Immunohistochemical evaluation of androgen receptors in genital and extragenital lichen sclerosus: evidence for loss of androgen receptors in lesional epidermis. J Am Acad Dermatol. 1999;41:43-6.
50. Günthert AR, Faber M, Knappe G, et al. Early onset vulvar lichen sclerosus in premenopausal women and oral contraceptives. Eur J Obstet Gynecol Reprod Biol. 2008;137:56-60.
51. Depasquale I, Park AJ, Bracka A. The treatment of balanitis xerotica obliterans. BJU Int. 2000;86:459-65.
52. Smith SD, Fischer G. Childhood onset vulvar lichen sclerosus does not resolve at puberty: a prospective case series. Pediatr Dermatol. 2009;26:725-9.
53. Powell J, Wojnarowska F. Childhood vulvar lichen sclerosus: the course after puberty. J Reprod Med. 2002;47:706-9.
54. Funaro D. Lichen sclerosus: a review and practical approach. Dermatol Ther. 2004;17:28-37.
55. Cooper SM, Gao XH, Powell JJ, et al. Does treatment of vulvar lichen sclerosus influence its prognosis? Arch Dermatol. 2004;140:702-6.
56. Lorenz B, Kaufman RH, Kutzner SK. Lichen sclerosus: therapy with clobetasol propionate. J Reprod Med. 1998;43:790-4.
57. Simpkin S, Oakley A. Clinical review of 202 patients with vulval lichen sclerosus: a possible association with psorasis. Australas J Dermatol. 2007;48:28-31.
58. Meyrick Thomas RH, Ridley CM, McGibbon DH, et al. Anogenital lichen sclerosus in women. J R Soc Med. 1996;89:694-8.
59. Schaffer JV, Orlow SJ. Melanocytic proliferations in the setting of vulvar lichen sclerosus: diagnostic considerations. Pediatr Dermatol. 2005;22:276-8.
60. Clark WH, Hood AF, Tucker MA, et al. Atypical melanocytic nevi of the genital type with a discussion of reciprocal parenchymal-stromal interactions in the biology of neoplasia. Hum Pathol. 1998;29(Suppl. 1):S1-24.
61. Carlson JA, Mu XC, Slominski A, et al. Melanocytic proliferations associated with lichen sclerosus. Arch Dermatol. 2002;138:77-87.
62. Dalziel KL. Effect of lichen sclerosus on sexual function and parturition. J Reprod Med. 1995;40:351-4.
63. Burrows LJ, Creasey A, Goldstein AT. The treatment of vulvar lichen sclerosus and female sexual dysfunction. J Sex Med. 2011;8:219-22.
64. Khachemoune A, Guldbakke KK, Ehrsam E. Infantile perineal protrusion. J Am Acad Dermatol. 2006;54:1046-9.
65. Aynaud O, Piron D, Casanova JM. Incidence of preputial lichen sclerosus in adults: histologic study of circumcision specimens. J Am Acad Dermatol. 1999;41:923-6.
66. Pugliese JM, Morey AF, Peterson AC. Lichen sclerosus: review of the literature and current recommendations for management. J Urol. 2007;178:2268-76.
67. Chalmers RJ, Burton PA, Bennett RF, et al. Lichen sclerosus et atrophicus: a common and distinctive cause of phimosis in boys. Arch Dermatol. 1984;120:1025-7.
68. Meuli M, Briner J, Hanimann B, et al. Lichen sclerosus et atrophicus causing phimosis in boys: a prospective study with 5-year followup after complete circumcision. J Urol. 1994;152:987-9.
69. Kiss A, Király L, Kutasy B, et al. High incidence of balanitis xerotica obliterans in boys with phimosis: prospective 10-year study. Pediatr Dermatol. 2005;22:305-8.
70. Regauer S, Liegl B, Reich O. Early vulvar lichen sclerosus: a histopathological challenge. Histopathology. 2005;47:340-7.
71. Regauer S, Liegl B, Reich H, et al. Vulvar lichen sclerosus: the importance of early clinical and histological diagnosis. Hautarzt. 2004;55:158-64.
72. Carlson JA, Lamb P, Malfetano J, et al. Clinicopathologic comparison of vulvar and extragenital lichen sclerosus: histologic variants, evolving lesions, and etiology of 141 cases. Mod Pathol. 1998;11:844-54.
73. Simonart T, Lahaye M, Simonart JM. Vulvar lichen sclerosus: effect of maintenance treatment with a moisturizer on the course of the disease. Menopause. 2008;15:74-7.
74. Cattaneo A, Carli P, De Marco A, et al. Testosterone maintenance therapy: effects on vulvar lichen sclerosus treated with clobetasol propionate. J Reprod Med. 1996;41:99-102.
75. Dalziel KL, Millard PR, Wojnarowska F. The treatment of vulval lichen sclerosus with a very potent topical steroid (clobetasol propionate 0.05%) cream. Br J Dermatol. 1991;124:461-4.
76. Dalziel KL, Wojnarowska F. Long-term control of vulval lichen sclerosus after treatment with a potent topical steroid cream. J Reprod Med. 1993;38:25-7.
77. Ayhan A, Guven S, Guvendag Guven ES, et al. Topical testosterone versus clobetasol for vulvar lichen sclerosus. Int J Gynaecol Obstet. 2007;96:117-21.
78. Smith YR, Haefner HK. Vulvar lichen sclerosus, pathophysiology and treatment. Am J Clin Dermatol. 2004;5:105-25.
79. Renaud-Vilmer C, Cavelier-Balloy B, Porcher R, et al. Vulvar lichen sclerosus: effect of long-term topical application of a potent steroid on the course of the disease. Arch Dermatol. 2004;140:709-12.
80. Cattaneo A, De Magnis A, Botti E, et al. Topical mometasone furoate for vulvar lichen sclerosus. J Reprod Med. 2003;48:444-8.
81. Lefevre C, Hoffstetter S, Meyer S, et al. Management of lichen sclerosus with triamcinolone ointment: effectiveness in reduction of patient symptom scores. J Low Genit Tract Dis. 2011;15:205-9.
82. Bradford J, Fischer G. Long-term management of vulval lichen sclerosus in adult women. Aust N Z J Obstet Gynaecol. 2010;50:148-52.
83. Fischer G, Rogers M. Treatment of childhood vulvar lichen sclerosus with potent topical corticosteroid. Pediatr Dermatol. 1997;14:235-8.
84. Garzon MC, Paller AS. Ultrapotent topical corticosteroid treatment of childhood genital lichen sclerosus. Arch Dermatol. 1999;135:525-8.
85. Smith YR, Quint EH. Clobetasol propionate in the treatment of premenarchal vulvar lichen sclerosus. Obstet Gynecol. 2001;98:588-91.
86. Patrizi A, Gurioli C, Medri M, et al. Childhood lichen sclerosus: a long-term follow-up. Pediatr Dermatol. 2010;27:101-3.
87. Dahlman-Ghozlan K, Hedblad MA, von Krogh G. Penile lichen sclerosus et atrophicus treated with clobetasol dipropionate 0.05% cream: a retrospective clinical and histopathological study. J Am Acad Dermatol. 1999;40:451-7.
88. Riddell L, Edwards A, Sherrard J. Clinical features of lichen sclerosus in men attending a department of genitourinary medicine. Sex Transm Infect. 2000;76:311-3.
89. Kiss A, Csontai A, Pirót L, et al. The response of balanitis xerotica obliterans to local steroid application compared with placebo in children. J Urol. 2001;165:219-20.
90. Vincent MV, Mackinnon E. The response of clinical balanitis xerotica obliterans to the application of topical steroid-based creams. J Pediatr Surg. 2005;40:709-12.
91. Jørgensen ET, Svensson A. The treatment of phimosis in boys, with a potent topical steroid (clobetasol propionate 0.05%) cream. Acta Derm Venereol. 1993;73:55-6.
92. Lindhagen T. Topical clobetasol propionate compared with placebo in the treatment of unretractable foreskin. Eur J Surg. 1996;162:969-72.
93. Yang SS, Tsai YC, Wu CC, et al. Highly potent and moderately potent topical steroids are effective in treating phimosis: a prospective randomized study. J Urol. 2005;173:1361-3.
94. Ghysel C, Vander Eeckt K, Bogaert GA. Long-term efficiency of skin stretching and a topical corticoid cream application for unretractable foreskin and phimosis in prepubertal boys. Urol Int. 2009;82:81-8.
95. Bunker CB. Comments on the British Association of Dermatologists guidelines for the management of lichen sclerosus. Br J Dermatol. 2011;164:894-5.
96. Fischer G, Bradford J. Topical immunosuppressants, genital lichen sclerosus and the risk of squamous cell carcinoma: a case report. J Reprod Med. 2007;52:329-31.
97. Commission on Human Medicines. Topical tacrolimus (protopic) and pimecrolimus (Elidel): reports of malignancies. Curr Probl Pharmacovigil. 2006;31:1-2.
98. Fistarol SK, Itin PH. Anti-inflammatory treatment. Curr Probl Dermatol. 2011;40:58-70.
99. Yesudian PD. The role of calcineurin inhibitors in the management of lichen sclerosus. Am J Clin Dermatol. 2009;10:313-8.
100. Goldstein AT, Marinoff SC, Christopher K. Pimecrolimus for the treatment of vulvar lichen sclerosus in a premenarchal girl. J Pediatr Adolesc Gynecol. 2004;17:35-7.
101. Boms S, Gambichler T, Freitag M, et al. Pimecrolimus 1% cream for anogenital lichen sclerosus in childhood. BMC Dermatol. 2004;4:14.
102. Goldstein AT, Marinoff SC, Christopher K. Pimecrolimus for the treatment of vulvar lichen sclerosus: a report of 4 cases. J Reprod Med. 2004;49:778-80.
103. Nissi R, Eriksen H, Risteli J, et al. Pimecrolimus cream 1% in the treatment of lichen sclerosus. Gynecol Obstet Invest. 2007;63:151-4.
104. Oskay T, Sezer HK, Genç C, et al. Pimecrolimus 1% cream in the treatment of vulvar lichen sclerosus in postmenopausal women. Int J Dermatol. 2007;46:527-32.
105. Nissi R, Kotila V, Knuuti E, et al. Altered p53 and Bcl-2 expression in keratinocytes of vulvar lichen sclerosus during pimecrolimus reatment. Br J Dermatol. 2009;161:958-60.
106. Kauppila S, Kotila V, Knuuti E, et al. The effect of topical pimecrolimus on inflammatory infiltrate in vulvar lichen sclerosus. Am J Obstet Gynecol 2010;202:181.e1-4.
107. Goldstein AT, Creasey A, Pfau R, et al. A double-blind, randomized controlled trial of clobetasol versus pimecrolimus in patients with vulvar lichen sclerosus. J Am Acad Dermatol. 2011;64:e99-104.
108. Kim CY, Kim JG, Oh CW. Treatment of oral lichen sclerosus with 1% pimecrolimus cream. Ann Dermatol. 2010;22:326-9.
109. Assmann T, Becker-Wegerich P, Grewe M, et al. Tacrolimus ointment for the treatment of vulvar lichen sclerosus. J Am Acad Dermatol. 2003;48:935-7.
110. Kunstfeld R, Kirnbauer R, Stingl G, et al. Successful treatment of vulvar lichen sclerosus with topical tacrolimus. Arch Dermatol. 2003;139:850-2.
111. Böhm M, Frieling U, Luger TA, et al. Successful treatment of anogenital lichen sclerosus with topical tacrolimus. Arch Dermatol. 2003;139:922-4.
112. Ginarte M, Toribio J. Vulvar lichen sclerosus successfully treated with topical tacrolimus. Eur J Obstet Gynecol Reprod Biol. 2005;123:123-4.
113. Luesley DM, Downey GP. Topical tacrolimus in the management of lichen sclerosus. BJOG. 2006;113:832-4.
114. Virgili A, Lauriola MM, Mantovani L, et al. Vulvar lichen sclerosus: 11 women treated with tacrolimus 0.1% ointment. Acta Derm Venereol. 2007;87:69-72.
115. Hengge UR, Krause W, Hofmann H, et al. Multicentre, phase II trial on the safety and efficacy of topical tacrolimus ointment for the treatment of lichen sclerosus. Br J Dermatol. 2006;155:1021-8.
116. Sotiriou E, Apalla Z, Patsatsi A, et al. Topical tacrolimus for recalcitrant vulvar lichen sclerosus. Eur J Dermatol. 2009;19:515-6.
117. Matsumoto Y, Yamamoto T, Isobe T, et al. Successful treatment of vulvar lichen sclerosus in a child with low-concentration topical tacrolimus ointment. J Dermatol. 2007;34:114-6.
118. Sideri M, Origoni M, Spinaci L, et al. Topical testosterone in the treatment of vulvar lichen sclerosus. Int J Gynaecol Obstet. 1994;46:53-6.
119. Cattaneo A, De Marco A, Sonni L, et al. Clobetasol vs. testosterone in the treatment of lichen sclerosus of the vular region. Minerva Ginecol. 1992;44:567-71.
120. Ayhan A, Guven ES, Guven S, et al. Testosterone versus clobetasol for maintenance of vulvar lichen sclerosus associated with varable degrees of squamous cell hyperplasia. Acta Obstet Gynecol Scand. 2007;86:715-9.
121. Bornstein J, Heifetz S, Kellner Y, et al. Clobetasol dipropionate 0.05% versus testosterone propionate 2% topical application for severe vulvar lichen sclerosus. Am J Obstet Gynecol. 1998;178:80-4.
122. Mangold R, Heilmann V, Rossmanith WG. Iatrogenic androgenization. Zentralbl Gynakol. 1998;120:515-7.
123. Joura EA, Zeisler H, Bancher-Todesca D, et al. Short-term effects of topical testosterone in vulvar lichen sclerosus. Obstet Gynecol. 1997;89:297-9.
124. Parker LU, Bergfeld WF. Virilization secondary to topical testosterone. Cleve Clin J Med. 1991;58:43-6.
125. Ayhan A, Urman B, Yüce K, et al. Topical testosterone for lichen sclerosus. Int J Gynaecol Obstet. 1989;30:253-5.
126. Romppanen U, Tuimala R, Ellmén J, et al. Oral treatment of vulvar dystrophy with an aromatic retinoid, etretinate. Geburtshilfe Frauenheilkd. 1986;46:242-7.
127. Mork NJ, Jensen P, Hoel PS. Vulval lichen sclerosus et atrophicus treated with etretinate (Tigason). Acta Derm Venereol. 1986;66:363-5.
128. Bousema MT, Romppanen U, Geiger JM, et al. Acitretin in the treatment of severe lichen sclerosus et atrophicus of the vulva: a double-blind, placebo-controlled study. J Am Acad Dermatol. 1994;30:225-31.
129. Virgili A, Corazza M, Bianchi A, et al. Open study of topical 0.025% tretinoin in the treatment of vulvar lichen sclerosus: one year of therapy. J Reprod Med. 1995;40:614-8.
130. Ioannides D, Lazaridou E, Apalla Z, et al. Acitretin for severe lichen sclerosus of male genitalia: a randomized, placebo controlled study. J Urol. 2010;183:1395-9.
131. Kulkarni S, Barbagli G, Kirpekar D, et al. Lichen sclerosus of the male genitalia and urethra: surgical options and results in a multicenter international experience with 215 patients. Eur Urol. 2009;55:945-54.
132. Reichrath J, Reinhold U, Tilgen W. Treatment of genito-anal leisons in inflammatory skin diseases with PUVA cream photochemotherapy: an open pilot study in 12 patients. Dermatology. 2002;205:245-8.
133. von Kobyletzki, Freitag M, Hoffmann K, et al. Balneophotochemotherapy with 8-methoxypsoralen in lichen sclerosis et atrophicus. Hautarzt. 1997; 48:488-91.
134. Dalmau J, Baselga E, Roé E, et al. Psoralen-UVA treatment for generalized prepubertal extragenital lichen sclerosus et atrophicus. J Am Acad. 2006;55(2 Suppl.):S56-8.
135. Valdivielso-Ramos M, Bueno C, Hernanz JM. Significant improvement in extensive lichen sclerosus with tacrolimus ointment and PUVA. Am J Clin Dermatol. 2008;9:175-9.
136. Beattie PE, Dawe RS, Ferguson J, et al. UVA1 phototherapy for genital lichen sclerosus. Clin Exp Dermatol. 2006;31:343-7.
137. Kreuter A, Gambichler T, Avermaete A, et al. Low-dose ultraviolet A1 phototherapy for extragenital lichen sclerosus: results of a preliminary study. J Am Acad Dermatol. 2002;46:251-5.
138. Colbert RL, Chiang MP, Carlin CS, et al. Progressive extragenital lichen sclerosus successfully treated with narrowband UV-B phototherapy. Arch Dermatol. 2007;143:19-20.
139. Hillemanns P, Untch M, Pröve F, et al. Photodynamic therapy of vulvar lichen sclerosus with 5-aminolevulinic acid. Obstet Gynecol. 1999;93:71-4.
140. Sotiriou E, Apalla Z, Patsatsi A, et al. Recalcitrant vulvar lichen sclerosis treated with aminolevulinic acid-photodynamic therapy: a report of five cases. J Eur Acad Dermatol Venereol. 2008;22:1398-9.
141. Zawislak AA, McCluggage WG, Donnelly RF, et al. Response of vulval lichen sclerosus and squamous hyperplasia to photodynamic treatment using sustained topical delivery of aminolevulinic acid from a novel bioadhesive patch system. Photodermatol Photoimmunol Photomed. 2009;25:111-3.
142. Sotiriou E, Panagiotidou D, Ioannidis D. An open trial of 5-aminolevulinic acid photodynamic therapy for vulvar lichen sclerosus. Eur J Obstet Gynecol Reprod Biol. 2008;141:187-8.
143. Olejek A, Steplewska K, Gabriel A, et al. Efficacy of photodynamic therapy in vulvar lichen sclerosus treatment based on immunohistochemical analysis of CD34, CD44, myelin basic protein, and Ki67 antibodies. Int J Gynecol Cancer. 2010;20:879-87.
144. Olejek A, Kozak-Darmas I, Kellas-Sleczka S, et al. Effectiveness of photodynamic therapy in the treatment of lichen sclerosus: cell changes in immunohistochemistry. Neuro Endocrinol Lett. 2009;30:547-51.
145. Hagedorn M, Golüke T, Mall G. Lichen sclerosus and squamous cell carcinoma of the vulva. J Dtsch Dermatol Ges. 2003;1:864-8.
146. Carli P, Cattaneo A, De Magnis A, et al. Squamous cell carcinoma arising in vulval lichen sclerosus: a longitudinal cohort study. Eur J Cancer Prev. 1995;4:491-5.
147. Jones RW, Sadler L, Grant S, et al. Clinically identifying women with vulvar lichen sclerosus at increased risk of squamous cell carcinoma: a case-control study. J Reprod Med. 2004;49:808-11.
148. Chiesa-Vottero A, Dvoretsky PM, Hart WR. Histopathologic study of thin vulvar squamous cell carcinomas and associated cutaneous lesions: a correlative study of 48 tumors in 44 patients with analysis of adjacent vulvar intraepithelial neoplasia types and lichen sclerosus. Am J Surg Pathol. 2006;30:310-8.
149. Nasca MR, Innocenzi D, Micali G. Penile cancer among patients with genital lichen sclerosus. J Am Acad Dermatol. 1999;41:911-4.
150. Micali G, Nasca MR, Innocenzi D. Lichen sclerosus of the glans is significantly associated with penile carcinoma [letter]. Sex Transm Infect. 2001;77:226.
151. Barbagli G, Palminteri E, Mirri F, et al. Penile carcinoma in patients with genital lichen sclerosus: a multicenter survey. J Urol. 2006;175:1359-63.
152. Powell J, Robson A, Cranston D, et al. High incidence of lichen sclerosus in patients with squamous cell carcinoma of the penis. Br J Dermatol. 2001;145:85-9.
153. Perceau G, Derancourt C, Clavel C, et al. Lichen sclerosus is frequently present in penile squamous cell carcinomas but is not always associated with oncogenic human papillomavirus. Br J Dermatol. 2003;148:934-8.
154. Velazquez EF, Cubilla AL. Lichen sclerosus in 68 patients with squamous cell carcinoma of the penis: frequent atypias and correlation with special carcinoma variants suggests a precancerous role. Am J Surg Pathol. 2003;27:1448-53.
155. ®, NDA 50-777) [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4089b2-01-06- Pimecrolimus%20Tacrolimus%20Malignancy%20Update%20Pitts%20PID%20040754%20040752. pdf. Accessed 23 Nov 2012.